Authors: Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Medical Oncology Division, University of Washington, Seattle.

Source: JAMA [JAMA] 2023 Mar 21; Vol. 329 (11), pp. 918-932.

Publication Type: Review; Journal Article

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

Authors: Kozaki R; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Yasuhiro T; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Kato H; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Murai J; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Hotta S; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Ariza Y; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Sakai S; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Fujikawa R; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan., Yoshida T; Discovery and Research, Ono Pharmaceutical Co., Ltd, Osaka, Japan.

Source: PloS one [PLoS One] 2023 Mar 10; Vol. 18 (3), pp. e0282166. Date of Electronic Publication: 2023 Mar 10 (Print Publication: 2023).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Authors: Ono T; Department of Transfusion and Cell Therapy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan., Takahashi N; Department of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, Akita, Japan., Kizaki M; Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan., Kawaguchi T; Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan., Suzuki R; Department of Hematology and Oncology, Faculty of Medicine, Shimane University, Izumo, Japan., Yamamoto K; Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan., Ohnishi K; Shubun University Faculty of Medical Sciences, Ichinomiya, Japan., Naoe T; National Hospital Organization, Nagoya Medical Center, Nagoya, Japan., Matsumura I; Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Source: Cancer science [Cancer Sci] 2023 Mar; Vol. 114 (3), pp. 995-1006. Date of Electronic Publication: 2022 Nov 23.

Publication Type: Clinical Trial; Journal Article

Journal Info: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE

Authors: Rajabto W; Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. wulyo02@gmail.com., Joenputri N

Source: Acta medica Indonesiana [Acta Med Indones] 2022 Oct; Vol. 54 (4), pp. 603-606.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Indonesian Society of Internal Medicine Country of Publication: Indonesia NLM ID: 7901042 Publication Model: Print Cited Medium: Internet ISSN: 0125-9326 (Print) Linking ISSN: 01259326 NLM ISO Abbreviation: Acta Med Indones Subsets: MEDLINE

Authors: Lei J; Guizhou Medical University, Guiyang, China., Yan T; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China., Zhang L; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China., Chen B; Peking University 302 Clinical Medical School, Beijing, China., Cheng J; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China., Gao X; Guizhou Medical University, Guiyang, China.; Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China., Liu Z; Peking University 302 Clinical Medical School, Beijing, China., Li Y; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China., Zuo S; Guizhou Medical University, Guiyang, China. drzuoshi@gmc.edu.cn.; Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China. drzuoshi@gmc.edu.cn., Lu Y; Guizhou Medical University, Guiyang, China. luyinying1973@163.com.; Comprehensive Liver Cancer Center, The 5th Medical Center of the PLA General Hospital, Beijing, China. luyinying1973@163.com.; Guangdong Key Laboratory of Epigenetics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, China. luyinying1973@163.com.

Source: Hepatology international [Hepatol Int] 2023 Apr; Vol. 17 (2), pp. 281-290. Date of Electronic Publication: 2022 Dec 29.

Publication Type: Comparative Study; Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101304009 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-0541 (Electronic) Linking ISSN: 19360533 NLM ISO Abbreviation: Hepatol Int Subsets: MEDLINE

MeSH Terms: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/virology , Hepatitis B*/physiopathology , Hepatitis B*/virology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/virology , Tyrosine Protein Kinase Inhibitors*/pharmacology , Tyrosine Protein Kinase Inhibitors*/therapeutic use , Virus Activation*/drug effects, Humans ; Hepatitis B virus/drug effects ; Hepatitis B virus/physiology ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use

Authors: Yang Z; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Liu C; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Hu Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Liu H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Li J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Wu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Liu Q; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Zheng Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Huang P; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China., Wang Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China. Electronic address: wangying1@ihcams.ac.cn.

Source: Leukemia research [Leuk Res] 2023 Apr; Vol. 127, pp. 107039. Date of Electronic Publication: 2023 Feb 12.

Publication Type: Letter; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

MeSH Terms: Blast Crisis*/drug therapy , Tyrosine Protein Kinase Inhibitors*, Humans ; Azacitidine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Fusion Proteins, bcr-abl ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology

Authors: Ebrahimi N; Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran., Fardi E; Medical Branch, Islamic Azad University of Tehran, Tehran, Iran., Ghaderi H; Laboratory of Regenerative and Medical Innovation, Pasteur Institute of Iran, Tehran, Iran., Palizdar S; Division of Microbiology, Faculty of Basic Sciences, Islamic Azad University of Tehran East Branch, Tehran, Iran., Khorram R; Bone and Joint Diseases Research Center, Department of Orthopedic Surgery, Shiraz University of Medical Sciences, Shiraz, Iran., Vafadar R; Department of Orthopeadic Surgery, Kerman University of Medical Sciences, Kerman, Iran., Ghanaatian M; Master 1 Bio-Santé-Parcours Toulouse Graduate School of Cancer, Ageing and Rejuvenation (CARe), Université Toulouse III-Paul Sabatier, Toulouse, France., Rezaei-Tazangi F; Department of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran., Baziyar P; Department of Molecular and Cell Biology, Faculty of Basic Science, Uinversity of Mazandaran, Babolsar, Iran., Ahmadi A; Department of Biological Science and Technology, Faculty of Nano and Bio Science and Technology, Persian Gulf University, Bushehr, 75169, Iran. ahahmadi@pgu.ac.ir., Hamblin MR; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, 2028, South Africa. labhamblin@gmail.com., Aref AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA. amir@xspherabio.com.; Translational Medicine Group, Xsphera Biosciences, 6 Tide Street, Boston, MA, 02210, USA. amir@xspherabio.com.

Source: Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2023 Mar 22; Vol. 80 (4), pp. 104. Date of Electronic Publication: 2023 Mar 22.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: Switzerland NLM ID: 9705402 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-9071 (Electronic) Linking ISSN: 1420682X NLM ISO Abbreviation: Cell Mol Life Sci Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Neoplasms*/drug therapy , Neoplasms*/metabolism, Humans ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/chemistry ; Receptor Protein-Tyrosine Kinases/metabolism ; Signal Transduction

Authors: Fauziya; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India., Gupta A; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India., Nadaf A; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India., Ahmad S; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India., Hasan N; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India., Imran M; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India., Sahebkar A; Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran., Jain GK; Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India., Kesharwani P; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. prashantdops@gmail.com.; Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Chennai, India. prashantdops@gmail.com., Ahmad FJ; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. fjahmad@jamiahamdard.ac.in.

Source: Medical oncology (Northwood, London, England) [Med Oncol] 2023 May 10; Vol. 40 (6), pp. 173. Date of Electronic Publication: 2023 May 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy, Humans ; Dasatinib/pharmacology ; Dasatinib/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Imatinib Mesylate/therapeutic use

Authors: Bidikian A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Source: American journal of hematology [Am J Hematol] 2023 Apr; Vol. 98 (4), pp. 639-644. Date of Electronic Publication: 2023 Jan 16.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics, Humans ; Treatment Outcome ; Fusion Proteins, bcr-abl/genetics ; Protein Kinase Inhibitors

Authors: Alshammari AH; Faculty of Pharmacy, Kakuma-machi, Kanazawa University, Kanazawa, 920-1192, Japan., Masuo Y; Faculty of Pharmacy, Kakuma-machi, Kanazawa University, Kanazawa, 920-1192, Japan., Yoshino S; Faculty of Pharmacy, Kakuma-machi, Kanazawa University, Kanazawa, 920-1192, Japan., Yamashita R; Faculty of Pharmacy, Kakuma-machi, Kanazawa University, Kanazawa, 920-1192, Japan., Ishimoto T; Faculty of Pharmacy, Kakuma-machi, Kanazawa University, Kanazawa, 920-1192, Japan., Fujita KI; School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Kato Y; Faculty of Pharmacy, Kakuma-machi, Kanazawa University, Kanazawa, 920-1192, Japan. Electronic address: ykato@p.kanazawa-u.ac.jp.

Source: Drug metabolism and pharmacokinetics [Drug Metab Pharmacokinet] 2023 Apr; Vol. 49, pp. 100483. Date of Electronic Publication: 2022 Nov 05.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101164773 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-0920 (Electronic) Linking ISSN: 13474367 NLM ISO Abbreviation: Drug Metab Pharmacokinet Subsets: MEDLINE

MeSH Terms: Dependovirus*/genetics , Dependovirus*/metabolism , Tyrosine Protein Kinase Inhibitors*, Mice ; Animals ; ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism ; ATP-Binding Cassette Transporters/genetics ; Neoplasm Proteins/metabolism ; Liver/metabolism ; Protein Kinase Inhibitors/metabolism ; RNA, Small Interfering/metabolism ; Mice, Knockout

Authors: Vinothkumar K; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India., Chanda S; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India.; Regional Centre for Biotechnology, Faridabad, Haryana, India., Singh VK; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India., Biswas S; Sparsh Hospital and Critical Care, Bhubaneswar, India., Mohapatra S; Department of Medical Oncology/Hematology, All India Institute of Medical Sciences, Bhubaneswar, India., Biswas G; Sparsh Hospital and Critical Care, Bhubaneswar, India., Chakraborty S; Cancer Biology Group, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India. soumen_ils@yahoo.co.in.; Regional Centre for Biotechnology, Faridabad, Haryana, India. soumen_ils@yahoo.co.in.

Source: International journal of hematology [Int J Hematol] 2023 Jan; Vol. 117 (1), pp. 110-120. Date of Electronic Publication: 2022 Oct 25.

Publication Type: Journal Article

Journal Info: Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE

MeSH Terms: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/metabolism , Tyrosine Protein Kinase Inhibitors*, Humans ; Apoptosis ; Cyclooxygenase 1/pharmacology ; Cyclooxygenase 1/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Fusion Proteins, bcr-abl ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; K562 Cells ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use

Authors: Indermun S; Department of Pharmacy and Pharmacology, Wits Advanced Drug Delivery Platform Research Unit, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa., Kumar P; Department of Pharmacy and Pharmacology, Wits Advanced Drug Delivery Platform Research Unit, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa., Govender M; Department of Pharmacy and Pharmacology, Wits Advanced Drug Delivery Platform Research Unit, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa., Choonara YE; Department of Pharmacy and Pharmacology, Wits Advanced Drug Delivery Platform Research Unit, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa.

Source: Current medicinal chemistry [Curr Med Chem] 2023; Vol. 30 (13), pp. 1482-1501.

Publication Type: Review; Journal Article

Journal Info: Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 9440157 Publication Model: Print Cited Medium: Internet ISSN: 1875-533X (Electronic) Linking ISSN: 09298673 NLM ISO Abbreviation: Curr Med Chem Subsets: MEDLINE

MeSH Terms: Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/chemistry , Neoplasms*/drug therapy, Humans ; Tyrosine Protein Kinase Inhibitors

Authors: Zheng FY; Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China., Wang M; Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China., Zhang LP; Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China., Jiang Q; Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China.

Source: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2023 Feb 14; Vol. 44 (2), pp. 174-176.

Publication Type: Journal Article

Journal Info: Publisher: Zhongguo yi xue ke xue yuan Country of Publication: China NLM ID: 8212398 Publication Model: Print Cited Medium: Print ISSN: 0253-2727 (Print) Linking ISSN: 02532727 NLM ISO Abbreviation: Zhonghua Xue Ye Xue Za Zhi Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy, Humans ; Child ; Protein Kinase Inhibitors/therapeutic use ; Chronic Disease

Authors: Lu CW; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan., Pang JS; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, Taiwan., Ko YS; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Cardiovascular Division, Chang Gung Memorial Hospital, Linkou, Taiwan.; Microscope Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan., Chang CJ; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; Allergology Consortium, Xiamen Chang Gung Hospital, Xiamen, Fujian, China.; Medical Research Center, Xiamen Chang Gung Hospital, Xiamen, Fujian, China.; School of Medicine, Huaqiao University, Quanzhou, Fujian, China., Wang CW; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan.; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China., Chen WT; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China., Chen CB; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan.; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China.; Chang Gung Immunology Consortium, Chang Gung University, Taiwan.; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan., Hui RC; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan., Hung SI; Allergology Consortium, Xiamen Chang Gung Hospital, Xiamen, Fujian, China.; Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan., Lu LY; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan., Lu KL; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan., Wang CL; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan., Wu CE; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Division of Hematology-Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan., Hsu PC; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan., Fang YF; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan., Li SH; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan., Ko HW; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Division of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan., Tseng LC; Department of Oncology Case Management, Chang Gung Memorial Hospital, Taoyuan, Taiwan., Shih FY; Department of Oncology Case Management, Chang Gung Memorial Hospital, Taoyuan, Taiwan., Chen MJ; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan., Chung WH; Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Taiwan.; Department of Dermatology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.; Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Source: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 Feb; Vol. 37 (2), pp. 328-339. Date of Electronic Publication: 2022 Nov 16.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE

MeSH Terms: Adenocarcinoma of Lung*/drug therapy , Exanthema*/chemically induced , Exanthema*/drug therapy , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Tyrosine Protein Kinase Inhibitors*/adverse effects , Zinc*/metabolism, Animals ; Mice ; Rats ; ErbB Receptors ; Erlotinib Hydrochloride/adverse effects ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies

Authors: Shodai A; Department of Hematology and Rheumatology, Kagoshima University Hospital., Tazaki Y; Department of Obstetrics & Gynecology, Faculty of Medicine, Kagoshima University., Uchida N; Department of Obstetrics & Gynecology, Faculty of Medicine, Kagoshima University., Hamada T; Department of Obstetrics & Gynecology, Faculty of Medicine, Kagoshima University., Akahoshi R; Department of Hematology and Rheumatology, Kagoshima University Hospital., Ueno T; Department of Hematology and Rheumatology, Kagoshima University Hospital., Tabuchi T; Department of Hematology and Rheumatology, Kagoshima University Hospital., Arima N; Department of Hematology and Rheumatology, Kagoshima University Hospital., Hayashida M; Department of Hematology and Rheumatology, Kagoshima University Hospital., Arai A; Department of Hematology and Rheumatology, Kagoshima University Hospital., Nakamura D; Department of Hematology and Rheumatology, Kagoshima University Hospital., Yoshimitsu M; Department of Hematology and Rheumatology, Kagoshima University Hospital.; Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University., Kobayashi H; Department of Obstetrics & Gynecology, Faculty of Medicine, Kagoshima University., Ishitsuka K; Department of Hematology and Rheumatology, Kagoshima University Hospital.; Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University.

Source: [Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2023; Vol. 64 (2), pp. 102-106.

Publication Type: Case Reports; English Abstract; Journal Article

Journal Info: Publisher: Japan Society Of Clinical Hematology Country of Publication: Japan NLM ID: 2984782R Publication Model: Print Cited Medium: Print ISSN: 0485-1439 (Print) Linking ISSN: 04851439 NLM ISO Abbreviation: Rinsho Ketsueki Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics, Humans ; Pregnancy ; Female ; Young Adult ; Adult ; Interferon-alpha/therapeutic use ; Fusion Proteins, bcr-abl/genetics ; Protein Kinase Inhibitors/therapeutic use ; Recurrence ; Treatment Outcome

Authors: Podoll T; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.) terry.podoll@iv-po.com., Pearson PG; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Kaptein A; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Evarts J; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., de Bruin G; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Emmelot-van Hoek M; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., de Jong A; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., van Lith B; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Sun H; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Byard S; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Fretland A; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Hoogenboom N; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Barf T; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Slatter JG; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.).

Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2023 Jan; Vol. 384 (1), pp. 173-186. Date of Electronic Publication: 2022 Oct 30.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Cytochrome P-450 CYP3A*, Humans ; Adult ; Agammaglobulinaemia Tyrosine Kinase ; ATP Binding Cassette Transporter, Subfamily G, Member 2 ; Cytochrome P-450 CYP2C9 ; Neoplasm Proteins ; Protein Kinase Inhibitors/therapeutic use

Transliterated Title: Nouvelles AMM : asciminib dans la LMC Ph+ après au moins deux inhibiteurs de tyrosine kinase.

Authors: Rey G; Centre hospitalier universitaire de Saint-Etienne, Service d'hématologie, Saint-Etienne, France. Electronic address: rey.gaelle.maud@gmail.com., Rousselot P; Université de Versaille Saint-Quentin-en-Yvelines, Service d'hématologie et d'oncologie, Hôpital Mignot, Versailles, France.

Source: Bulletin du cancer [Bull Cancer] 2023 Jan; Vol. 110 (1), pp. 13-15. Date of Electronic Publication: 2022 Nov 22.

Publication Type: Letter

Journal Info: Publisher: Elsevier Country of Publication: France NLM ID: 0072416 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1769-6917 (Electronic) Linking ISSN: 00074551 NLM ISO Abbreviation: Bull Cancer Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Antineoplastic Agents*/adverse effects, Humans ; Adult ; Drug Approval ; Pyrazoles/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Drug Resistance, Neoplasm ; Fusion Proteins, bcr-abl

Authors: Umezawa Y; Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX, 77030, USA. ksasaki1@mdanderson.org.

Source: International journal of hematology [Int J Hematol] 2023 Jan; Vol. 117 (1), pp. 24-29. Date of Electronic Publication: 2022 Sep 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE

MeSH Terms: Tyrosine Protein Kinase Inhibitors* , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy, Humans ; Protein Kinase Inhibitors/adverse effects ; Molecular Targeted Therapy

Authors: Cortes J; Georgia Cancer Center, Augusta, Georgia.

Source: Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2023 May; Vol. 21 (5), pp. 240-243.

Publication Type: Interview

Journal Info: Publisher: Millennium Medical Pub Country of Publication: United States NLM ID: 101167661 Publication Model: Print Cited Medium: Internet ISSN: 1543-0790 (Print) Linking ISSN: 15430790 NLM ISO Abbreviation: Clin Adv Hematol Oncol Subsets: MEDLINE

Authors: Dybowski S; Institute of Neuropathology, University Medical Center, Göttingen, Germany., Torke S; Institute of Neuropathology, University Medical Center, Göttingen, Germany.; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Weber MS; Institute of Neuropathology, University Medical Center, Göttingen, Germany.; Department of Neurology, University Medical Center, Göttingen, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology, Göttingen, Germany.

Source: JAMA neurology [JAMA Neurol] 2023 Apr 01; Vol. 80 (4), pp. 404-414.

Publication Type: Review; Journal Article

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE